Pharmacotherapeutic advances in the treatment of erectile dysfunction.
An estimated 20 million to 30 million American men have erectile dysfunction (ED). The past 2 decades of research defining erectile physiology and investigating the pathogenesis of ED have led to the recognition of a predominantly vascular basis for organic male sexual dysfunction. These scientific advances have laid the foundation for the advent of pharmacotherapies. The Food and Drug Administration approval of intracavernosal, intraurethral, and oral pharmacotherapeutics for ED has revolutionized non-surgical management of this condition. The primary care physician is faced with the challenges of diagnosis and treatment of ED, as well as referral of patients to urologists. In this article, erectile physiology and pathophysiology are reviewed, and pharmacotherapeutics are classified and discussed by their mechanisms of action and the means of administration. A thorough understanding of these new therapeutic options is key to the accurate diagnosis and successful treatment of ED and maximal patient satisfaction and care.
Department of Urology, Mayo Clinic Rochester, Minn. 55905, USA.
A
A
Nehra
D M
DM
Barrett
R B
RB
Moreland
D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use; D000242:Cyclic AMP / Q000096:biosynthesis; D006152:Cyclic GMP / Q000096:biosynthesis; D007172:Erectile Dysfunction / Q000188:drug therapy* / Q000209:etiology* / Q000473:pathology / Q000503:physiopathology; D005355:Fibrosis / Q000150:complications; D006801:Humans; D008297:Male; D010410:Penile Erection / Q000502:physiology; D010413:Penis / Q000473:pathology; D010726:Phosphodiesterase Inhibitors / Q000627:therapeutic use
D000317:Adrenergic alpha-Antagonists; D010726:Phosphodiesterase Inhibitors; D000242:Cyclic AMP; D006152:Cyclic GMP